Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Bristol Myers Squibb may be leading the way when it comes to pursuing cereblon E3 ligase modulator (CELMoD) drugs, but today, the pharma is standing tall.  | Bristol Myers Squibb may have gone big in ...

AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the drug candidate to a 62% improvement in survival among a prespecified subgroup of patients with light ...

Boston remains biotech's most influential hub, but the questions facing the region are increasingly global. Recorded live at Fierce Biotech Week in Boston, this panel discussion brings together Uli ...

Irish CRO Icon has closed the book on its investigation into its accounting practices and restated its consolidated ...

Novartis may be launching an array of vehicles to shuttle drugs across the blood-brain barrier, but executives told Fierce ...

The FDA has delayed its approval decision on Beren Therapeutics’ rare disease drug candidate, extending the asset’s long path ...

D&D Pharmatech has linked its GLP-1/glucagon dual receptor agonist to improvements in liver health, keeping the Korean ...

Hoth Therapeutics’ search for salvation in the stars appears to have been rewarded by investors, as the company’s stock ...

Human Longevity, which is seeking to use biology and genomics to boost the human lifespan, has launched a new company called ...

Dexcom warned that some lots of its G7 wearable glucose monitors were stolen on their way to the scrapyard and were sold by a ...

GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly ...